Palavra-chave: CHRONIC MYELOID LEUKEMIA

BCR-ABL1 STEM CELL TRANSPLANTATION CYTARABINE PH CHROMOSSOME NILOTINIB EUTOS SCORE IMATINIB RESISTANCE EXPRESSION PF P190 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION T315L OCULAR SUBOPTIMAL RESPONSES MITOXANTRONE ENESTND T315I B3A2 DHPLC MOLECULAR RESPONSE DASATINIB-TREATED F359V LASOR CYTOGENETIC PHASE 2 P190, P120, P230 MOLECULAR TRANSPORTER GENES NON-MYELOABLATIVE EXON 6 GLEEVEC CML START IMATINIB MESILATE BCR-ABL STATE UNIVERSITY OF CAMPINAS MUTATION BRAZILIAN MEDICAL ASSOCIATION DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY GENE EXPRESSION PROFILE INTERFERON-ALPHA TYROSINE KINASE COVID19 IMATINIB-RESISTANT OR-INTOLERANT K562 CELLS CHRONIC PHASE DISCONTINUATION EBMT RISK SCORES D-HPLC IMATINIB-RESISTANT IRS-1 JAK2 V617F POLYMORPHISMS TREATMENT-FREE REMISSION RT-PCR EBMT TK INHIBITORS DASATINIB AUTOGRAFTING NEW DRUGS TYROSINE KINASE INHIBITORS SECOND-GENERATION CLINICAL TRIAL FEDERAL UNIVERSITY OF MINAS GERAIS FISH HMGCLL1 PROGRESSION-FREE SURVIVAL AUTOGRAFTING OF PERIPHERAL-BLOOD EXPANDING NILOTINIB ACESS IN CLINICAL TRIALS IMATINIB PERIPHERAL BLOOD STEM CELL TRANSPLANTS BONE MARROW TRANSPLANTATION